METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug shows promise for tough prostate cancer
Disease control CompletedThis study tested a radioactive drug called 177Lu-PSMA-617 in 62 Chinese men with advanced prostate cancer that had spread and stopped responding to hormone therapy and chemotherapy. The drug targets a protein on cancer cells and delivers radiation directly to them. Researchers m…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental combo aims to outsmart resistant prostate cancer
Disease control CompletedThis study tested an experimental drug called CPI-1205 combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in 175 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and stopped responding to usual horm…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Finland's prostate cancer patterns revealed in large data review
Knowledge-focused CompletedThis completed study looked at over 1,000 men with metastatic prostate cancer in the Pirkanmaa region of Finland. Researchers analyzed patient characteristics, treatments used, and outcomes to better understand the disease burden. The goal was to fill gaps in knowledge about how …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC